Transcript of Analysts/Investors Call pertaining to the Financial Results for the quarter and Financial Year ended March 31, 2026
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 03 Jun 2026, 06:32 PM IST · BSE ID: cdf44c0c-5f98-4dd2-943b-21504fc8f056
View Original BSE Filing (PDF)
💡
In Simple Terms
The company held an analyst call to discuss its FY26 financial results, reporting strong revenue and profit growth driven by acquisitions.
🤖 AI Summary
- Consolidated revenue for FY26 reached approximately INR 142 crores, with a PAT of nearly INR 60 crores.
- 3B India's molecular diagnostic business sales grew by approximately 10% to INR 86.47 crores in FY26.
- TRUPCR Europe reported sales of GBP 1.75 million (INR 20.67 crores) in FY26, up from GBP 1.28 million.
- Coris BioConcept contributed consolidated sales of INR 35.91 crores and PAT of INR 8.76 crores for seven months.
- Management is targeting 15% to 20% growth for FY27, focusing on global expansion and regulatory approvals.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue FY26
INR 142 crores
Consolidated PAT FY26
INR 60 crores
3B India Molecular Diagnostic Sales FY26
INR 86.47 crores
10%
TRUPCR Europe Sales FY26
GBP 1.75 million (INR 20.67 crores)
Coris BioConcept Sales (7 months FY26)
INR 35.91 crores
Coris BioConcept PAT (7 months FY26)
INR 8.76 crores
🏢 How This Affects the Company
The company's acquisition of Coris BioConcept in August FY26 significantly contributed to consolidated revenue and profitability, expanding its global product portfolio. Continued focus on IVDR transition and US FDA submission for AMR products is central to expanding market access.
FY26 consolidated revenue was approximately INR 142 crores, with PAT of nearly INR 60 crores. Coris BioConcept contributed INR 35.91 crores in sales and INR 8.76 crores in PAT for the seven months post-acquisition, impacting overall profitability. The company expects tax benefits from Coris's carry forward losses for three to four years.
The company is integrating Coris BioConcept, rationalizing product costs, and navigating IVDR transition for key product families. Establishing tie-ups for clinical trials related to US FDA submission indicates progress in product development and regulatory compliance.
Reliance on seasonal flu and dengue/chikungunya demand for domestic growth presents a business variability risk. Geopolitical tensions in the Middle East impacted export markets, highlighting regional market risks. The timeframe for US FDA approval remains uncertain, affecting market access timelines.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this transcript filing.
👤
Who Is Affected
Shareholders are provided with management's detailed commentary on the company's Q4 and FY26 financial performance, influencing their understanding of company strategy and outlook.
🔍
Management Signal
Management signals a strategic focus on expanding global presence through acquisitions, regulatory approvals, and increased penetration in diagnostic markets.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
FY27 Q1 results — check for progress towards 15-20% growth target.
Update on US FDA submission for AMR products — monitor approval timeline.
Status of IVDR transition for key product families — assess regulatory compliance.
MEDIUM RISK
Growth targets depend on successful regulatory clearances and managing market competition and seasonality.
💡 Investor Takeaway
3B BlackBio Dx Ltd reported FY26 consolidated revenue of approximately INR 142 crores and PAT of nearly INR 60 crores. 3B India's molecular diagnostic business grew 10% to INR 86.47 crores. TRUPCR Europe sales reached GBP 1.75 million. The company targets 15% to 20% growth in FY27.
⚖️ Strengths & Concerns
✅ Positives
- FY26 consolidated revenue of approximately INR 142 crores and PAT of nearly INR 60 crores reflect strong overall financial performance.
- TRUPCR Europe delivered consistent growth with a CAGR of approximately 40% over four years, achieving GBP 1.75 million sales in FY26.
⚠️ Concerns
- 3B India's molecular diagnostic business growth of approximately 10% was lower than projections due to reduced seasonal demand and geopolitical tensions.
- Coris BioConcept's EBITDA is currently on the lower side due to high cost of employment, requiring structural changes.
📅 Company Track Record
3B BlackBio Dx Ltd (formerly Kilpest India Limited) released its Q4/FY26 results analyst call audio recording on June 1, 2026. This transcript provides further detail on the financial performance, including the impact of the Coris BioConcept acquisition in August of the previous financial year.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were 3B BlackBio Dx Ltd's consolidated revenue and PAT for FY26?
3B BlackBio Dx Ltd reported consolidated revenue of approximately INR 142 crores and a PAT of nearly INR 60 crores for the financial year ended March 31, 2026.
How much did 3B India's molecular diagnostic business grow in FY26?
3B India's molecular diagnostic business grew by approximately 10% in FY26, reaching sales of INR 86.47 crores compared to INR 78.34 crores in the previous year.
What were the sales for TRUPCR Europe in FY26?
TRUPCR Europe's sales reached GBP 1.75 million, which translates to INR 20.67 crores, during FY26.
What was Coris BioConcept's contribution to consolidated sales for the seven months in FY26?
Coris BioConcept contributed consolidated sales of INR 35.91 crores and a PAT of INR 8.76 crores for the seven months post-acquisition in FY26.
What growth target has 3B BlackBio Dx Ltd set for FY27?
3B BlackBio Dx Ltd is targeting 15% to 20% growth for the financial year 2026-27.
Questions based on this BSE filing only. For information purposes.